Treatment with the investigational anti-tau monoclonal antibody semorinemab significantly slowed decline in a measure of cognition among people with mild-to-moderate Alzheimer’s disease in the Phase 2 LAURIET clinical trial, top-line results show. “The top line results of the Lauriet Phase 2 clinical trial of semorinemab are remarkable in that it is the first time we have seen a therapeutic effect by a monoclonal anti-Tau antibody therapy,” Andrea Pfeifer, PhD, CEO at AC Immune, said in a…
You must be logged in to read/download the full post.
The post Semorinemab Slows Decline in Cognition, Top-line Results Show appeared first on BioNewsFeeds.